Allspring Global Investments Holdings LLC Sells 331,668 Shares of Hologic, Inc. (NASDAQ:HOLX)

Allspring Global Investments Holdings LLC decreased its stake in Hologic, Inc. (NASDAQ:HOLX) by 60.9% during the 4th quarter, HoldingsChannel reports. The fund owned 212,501 shares of the medical equipment provider’s stock after selling 331,668 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Hologic were worth $15,183,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Vanguard Group Inc. lifted its position in shares of Hologic by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 27,882,301 shares of the medical equipment provider’s stock worth $2,141,919,000 after acquiring an additional 381,608 shares during the period. BlackRock Inc. lifted its position in Hologic by 1.2% in the first quarter. BlackRock Inc. now owns 23,762,174 shares of the medical equipment provider’s stock worth $1,917,607,000 after purchasing an additional 282,787 shares during the period. State Street Corp boosted its stake in Hologic by 0.8% during the first quarter. State Street Corp now owns 11,426,634 shares of the medical equipment provider’s stock worth $877,794,000 after buying an additional 94,561 shares in the last quarter. Macquarie Group Ltd. increased its holdings in Hologic by 227.2% in the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after buying an additional 4,363,687 shares during the period. Finally, Victory Capital Management Inc. raised its stake in shares of Hologic by 8.9% in the 3rd quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider’s stock valued at $335,763,000 after buying an additional 393,371 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Price Performance

Shares of HOLX stock opened at $77.54 on Tuesday. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $87.88. The stock has a market capitalization of $18.20 billion, a PE ratio of 36.75, a PEG ratio of 2.62 and a beta of 1.00. The company has a debt-to-equity ratio of 0.55, a quick ratio of 3.18 and a current ratio of 3.89. The stock’s fifty day moving average is $75.64 and its 200-day moving average is $72.42.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $989.32 million. During the same quarter in the prior year, the firm earned $1.07 EPS. The company’s revenue was down 5.7% on a year-over-year basis. Equities research analysts expect that Hologic, Inc. will post 4.02 EPS for the current fiscal year.

Insider Activity at Hologic

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director Scott T. Garrett sold 16,441 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company’s stock, valued at approximately $3,670,130.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of Hologic stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the sale, the director now owns 1,572 shares of the company’s stock, valued at approximately $119,802.12. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock valued at $2,473,443 over the last quarter. Corporate insiders own 1.75% of the company’s stock.

Analysts Set New Price Targets

HOLX has been the topic of a number of analyst reports. William Blair reissued an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. StockNews.com cut Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. Raymond James boosted their price target on Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research note on Friday, February 2nd. UBS Group upped their price target on Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Friday, February 2nd. Finally, Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $87.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.